Astellas Applies To Market Bladder Drug Mirabegron In Japan
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma has applied for local approval of its YM178 (mirabegron) drug for treating overactive bladder disorders
You may also be interested in...
Goldman Sachs Gains 2 Board Seats With Burst Subscription Oral Care Investment
Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.
Health And Wellness Trademark Review 26 May, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Amivas Bests La Jolla In Race For US Approval Of Antimalarial Artesunate
La Jolla’s formulation appears blocked by Amivas’ seven-year orphan exclusivity, and the company also will miss out on chance for a tropical disease priority review voucher; Amivas worked with the US Army to bring the severe malaria treatment through final stages of development and regulatory review.
Need a specific report? 1000+ reports available
Buy Reports